New hope for ovarian cancer: experimental combo targets relapsed disease
NCT ID NCT07370818
First seen Jan 28, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tests a new drug called JPI-547 combined with bevacizumab in 81 people with ovarian cancer that has come back after prior treatment with platinum chemotherapy and PARP inhibitors. The goal is to find the best dose and see if the combination can delay cancer growth. Participants must have a specific type of ovarian cancer and known BRCA or HRD status.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.